The overactive bladder treatment market was valued at $2,426.40 million in 2021 and is estimated to reach $3,465.22 million by 2031, exhibiting a CAGR of 3.6% from 2022 to 2031.
Overactive bladder (OAB) may be defined as a condition which is characterized by a group of urinary symptoms. The condition causes a frequent and sudden urge to urinate which is difficult to control. Also, the person may feel an urge to urinate several times during the day as well as nighttime. It can also be characterized by unintentional loss of urine. Though it affects population of both genders but is more prominent in women. Its symptoms include urgent and uncontrollable need to urinate, frequent involuntary loss of urine, frequent urination, and others. These symptoms can be variable depending on the condition and the individual, which makes it difficult for the healthcare provider to diagnose the condition. Several medications are available in the market for treating the overactive bladder that can help relax the bladder and reduce symptoms of OAB.
Major factors driving the growth of overactive bladder treatment market include the rise in incidence of overactive bladder, increase in prevalence of bladder stones and bladder tumor, and increase in R&D activities in the pharmaceutical field. There is a huge rise in incidence of overactive bladder in the population around the globe. This rise is attributed to an increase in several pathological conditions causing overactive bladder. Neurological disorders such as stroke and multiple sclerosis, urinary tract infection that causes frequent and excessive urination, diabetes, and hormonal changes in women during menopause, are some of the major factors causing overactive bladder.
For instance, according to an article published by Cleveland Clinic in 2022, overactive bladder is a common condition in the U.S., and it affects up to 33 million adults, which include as many as 30% men and 40% women. This boosts the growth of the overactive bladder treatment market. In addition, conditions such as enlarged prostate, constipation and previous surgery done to treat incontinence are also some of the factors causing overactive bladder. Thus, the presence of huge number of factors causing overactive bladder increases its incidences in population all around the globe. This increases the demand for treatment medications and further propels the growth of the overactive bladder treatment market.
Furthermore, the increase in R&D activities in the pharmaceutical field is boosting the growth of the market. In recent years there has been a huge rise in research activities to develop and innovate new treatment options for various diseases. Research has been carried out to discover more about the pathology of the overactive bladder and its causes. Based on detail study, drugs and molecules has been developed by the scientist to target symptoms and thus offer new entities for treatment of the condition. This is anticipated to boost the market.
In addition, investments have been made by the key market players to establish advanced manufacturing techniques for development of medication. This makes it possible for the key players to offer high quality medications to the customers, which increases its efficacy and positive results in the patient. This further raises its demand for the treatment of overactive bladder, and thus boosts the market growth. Also, key market players are shifting their focus towards emerging countries which are anticipated to expand the market during the forecast period. Investments in emerging countries will offer lucrative opportunities for the market growth owing to the increasing healthcare spending, presence of favorable government facilities, and presence of raw materials in abundance in this region.
In addition, increasing healthcare expenditure and developing healthcare facilities in regions such as Asia-Pacific, is anticipated to boost the overactive bladder market during the forecast period. Although various key factors are driving the growth of the market, the presence of few factors such as lack of awareness about overactive bladder and some side effects associated with the medications is providing hindrance to the growth of the market. There is a very low awareness about the condition among the population in underdeveloped countries. People here are unaware about the condition and also its available treatment options. In addition, the presence of alternate treatment options such as pelvic floor physical therapy and surgery is also causing hindrance to the market growth.
The overactive bladder treatment market is segmented by drug class, disease type, distribution channel and region. By drug class, the market is categorized into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox, and others. On the basis of disease type, the market is segregated into idiopathic overactive bladder and neurogenic overactive bladder. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major Key players that operate in the overactive bladder treatment market are AbbVie Inc., Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin, Pfizer Inc., Sumitomo Pharma Co., Ltd, Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Limited.
Overactive bladder (OAB) may be defined as a condition which is characterized by a group of urinary symptoms. The condition causes a frequent and sudden urge to urinate which is difficult to control. Also, the person may feel an urge to urinate several times during the day as well as nighttime. It can also be characterized by unintentional loss of urine. Though it affects population of both genders but is more prominent in women. Its symptoms include urgent and uncontrollable need to urinate, frequent involuntary loss of urine, frequent urination, and others. These symptoms can be variable depending on the condition and the individual, which makes it difficult for the healthcare provider to diagnose the condition. Several medications are available in the market for treating the overactive bladder that can help relax the bladder and reduce symptoms of OAB.
Major factors driving the growth of overactive bladder treatment market include the rise in incidence of overactive bladder, increase in prevalence of bladder stones and bladder tumor, and increase in R&D activities in the pharmaceutical field. There is a huge rise in incidence of overactive bladder in the population around the globe. This rise is attributed to an increase in several pathological conditions causing overactive bladder. Neurological disorders such as stroke and multiple sclerosis, urinary tract infection that causes frequent and excessive urination, diabetes, and hormonal changes in women during menopause, are some of the major factors causing overactive bladder.
For instance, according to an article published by Cleveland Clinic in 2022, overactive bladder is a common condition in the U.S., and it affects up to 33 million adults, which include as many as 30% men and 40% women. This boosts the growth of the overactive bladder treatment market. In addition, conditions such as enlarged prostate, constipation and previous surgery done to treat incontinence are also some of the factors causing overactive bladder. Thus, the presence of huge number of factors causing overactive bladder increases its incidences in population all around the globe. This increases the demand for treatment medications and further propels the growth of the overactive bladder treatment market.
Furthermore, the increase in R&D activities in the pharmaceutical field is boosting the growth of the market. In recent years there has been a huge rise in research activities to develop and innovate new treatment options for various diseases. Research has been carried out to discover more about the pathology of the overactive bladder and its causes. Based on detail study, drugs and molecules has been developed by the scientist to target symptoms and thus offer new entities for treatment of the condition. This is anticipated to boost the market.
In addition, investments have been made by the key market players to establish advanced manufacturing techniques for development of medication. This makes it possible for the key players to offer high quality medications to the customers, which increases its efficacy and positive results in the patient. This further raises its demand for the treatment of overactive bladder, and thus boosts the market growth. Also, key market players are shifting their focus towards emerging countries which are anticipated to expand the market during the forecast period. Investments in emerging countries will offer lucrative opportunities for the market growth owing to the increasing healthcare spending, presence of favorable government facilities, and presence of raw materials in abundance in this region.
In addition, increasing healthcare expenditure and developing healthcare facilities in regions such as Asia-Pacific, is anticipated to boost the overactive bladder market during the forecast period. Although various key factors are driving the growth of the market, the presence of few factors such as lack of awareness about overactive bladder and some side effects associated with the medications is providing hindrance to the growth of the market. There is a very low awareness about the condition among the population in underdeveloped countries. People here are unaware about the condition and also its available treatment options. In addition, the presence of alternate treatment options such as pelvic floor physical therapy and surgery is also causing hindrance to the market growth.
The overactive bladder treatment market is segmented by drug class, disease type, distribution channel and region. By drug class, the market is categorized into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox, and others. On the basis of disease type, the market is segregated into idiopathic overactive bladder and neurogenic overactive bladder. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major Key players that operate in the overactive bladder treatment market are AbbVie Inc., Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin, Pfizer Inc., Sumitomo Pharma Co., Ltd, Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the overactive bladder treatment market analysis from 2021 to 2031 to identify the prevailing overactive bladder treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the overactive bladder treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global overactive bladder treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
- Anti-Cholinergic Drugs
- Beta-3 adrenergic drugs
- Botox
- Others
By Diseases type
- Idiopathic Bladder Overactivity
- Neurogenic Bladder Overactivity
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Korea
- Rest of LAMEA
Key Market Players
- AbbVie Inc.
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Limited
- Cipla Ltd
- Lupin
- Sumitomo Pharma Co., Ltd
- Astellas Pharma Inc.
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Alembic Pharmaceuticals Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS
CHAPTER 5: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE
CHAPTER 6: OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: OVERACTIVE BLADDER TREATMENT MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report titled, “Overactive Bladder Treatment Market," the overactive bladder treatment market was valued at $2.4 billion in 2021, and is estimated to reach $3.5 billion by 2031, growing at a CAGR of 3.6% from 2022 to 2031.The overactive bladder treatment market is likely to experience a significant growth rate of 3.6% from 2022-2031 owing to increasing market demand from pharmaceutical sector.
Overactive bladder is a urological condition characterized by frequent and sudden urge for urination. It is mainly associated with diseases such as diabetes, urinary tract infections, bladder tumor, bladder stones and others. In addition, it is also caused due to lifestyle changes such as alcoholism and obesity. Though the condition occurs in both genders, it is more prominent in women and in aged population. This condition can be treated using medications and dietary changes. Moreover, treating overactive bladder further helps reduce the incidence of incontinence.
Key factors driving the growth of the overactive bladder treatment market include rise in incidences of overactive bladder, increase in prevalence of bladder tumors and bladder stones, and increase in R&D activities. In addition, rise in awareness among the population regarding overactive bladder and its treatment options is also boosting the market growth. As awareness about overactive bladder grows, more patients are seeking medical help for treating the symptoms. Also, the prevalence of overactive bladder is increasing globally, particularly among the aging population. This is leading to a higher demand for effective treatments of the condition, which is driving the growth of the overactive bladder treatment market. Moreover, development of highly efficient and potent Botox medications for treatment of overactive bladder and its increasing demand among the population is also driving the growth of overactive bladder treatment market.
The market also offers growth opportunities to the key players in the market. Due to the rising demand for drugs and treatments for overactive bladder treatment and to meet these nations' unmet medical requirements, the key market players from developed regions have shifted their attention to developing nations like China and India. Moreover, China and India are two of the world's most populous countries, and thus represents a large potential market for healthcare products and services. Also, the governments in developing nations are increasingly investing in healthcare infrastructure and programs to improve the health of its citizens. This is creating new opportunities for healthcare companies to participate in these initiatives and expand its business in this region.
In addition, the key market players are focusing in R&D activities to develop products which are highly efficient in the treatment of over active bladder. Key players are focusing on formulating medications which are most effective and have affordable cost as compared to medications present in the market. This is further anticipated to offer lucrative opportunities for the key players in the market.
The overactive bladder treatment market is segmented by drug class, disease type, distribution channel and region. By drug class, the market is categorized into anti-cholinergic drugs, beta-3 adrenergic drugs, botox, and others. On the basis of disease type, the market is segregated into idiopathic overactive bladder and neurogenic overactive bladder. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include AbbVie Inc., Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin, Pfizer Inc., Sumitomo Pharma Co., Ltd, Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Limited. The players in the market have been actively engaged in the adoption various strategies such as acquisition, collaboration, branding, product development, expansion, clinical trials, agreement, partnership, product launch and product approval to remain competitive and gain advantage over the competitors in the market. For instance, in June 2020, AbbVie announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA). The application was to expand the BOTOX prescribing information for the treatment of detrusor (bladder muscle) overactivity associated with the neurologic conditions such as spina bifida and spinal cord injuries in pediatric patients.
Key Market Insights
- By drug class, the beta-3 adrenergic drugs segment was the highest revenue contributor to the market and is estimated to reach $1485.22 million by 2031, with a CAGR of 1.5%. However, the anti-cholinergic drugs segment is estimated to be the fastest-growing segment with a CAGR of 6.9% during the forecast period.
- By disease type, the idiopathic bladder overactivity segment dominated the global market. However, the neurogenic bladder overactivity segment is expected to be the fastest-growing segment during the forecast period.
- By distribution channel, the drug stores and retail pharmacies segment was the highest revenue contributor to the market with a CAGR of 3.0% during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- AbbVie Inc.
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Limited
- Cipla Ltd
- Lupin
- Sumitomo Pharma Co., Ltd
- Astellas Pharma Inc.
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Alembic Pharmaceuticals Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Related Reports
Overactive Bladder Treatment Global Market Report 2024
- Report
- 200 Pages
- Global
From
From
From
From
Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
- Report
- 271 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
